Drug-coated balloon angioplasty versus drug-eluting stent implantation in ACS patients with different angiographic patterns of in-stent restenosis

被引:2
作者
Xie, Haifang [1 ]
Qiu, Miaohan [1 ]
Li, Xinyan [1 ]
Xiao, Yao [1 ]
Mu, Yanyan [1 ]
Wang, Geng [1 ]
Han, Yaling [1 ]
机构
[1] Gen Hosp Northern Theater Command, Dept Cardiol, China 83 Wenhua Rd, Shenyang 110840, Liaoning, Peoples R China
关键词
Drug-coated balloon; Drug-eluting stent; Recurrent in-stent restenosis; Percutaneous coronary intervention; Angiography; CORONARY-ARTERY-DISEASE; RANDOMIZED-TRIAL; MULTICENTER; CATHETER; CLASSIFICATION; OUTCOMES; TERM;
D O I
10.1016/j.ijcard.2024.132450
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Drug-coated balloon (DCB) angioplasty and drug-eluting stents (DES) are two widely used treatments for in-stent restenosis (ISR). Focal and non-focal types of ISR affect the clinical outcomes. The present study aims to compare DES reimplantation versus DCB angioplasty in acute coronary syndrome (ACS) patients with focal ISR and non-focal ISR lesions. Methods: Patients with ISR lesions underwent percutaneous coronary intervention (PCI) were retrospectively evaluated and divided into DES group and DCB group. The primary endpoint was the incidence of target lesion failure (TLF) at 24 months follow up. Propensity score matching (PSM) was conducted to balance the baseline characteristics. Results: For focal ISR, TLF was comparable in the DES and DCB groups at 24 months of follow-up (Before PSM, hazard ratio [HR]: 0.70; 95% confidence interval [CI]: 0.39-1.27; p = 0.244; After PSM, HR: 0.83; 95% CI: 0.40-1.73; p = 0.625). For non-focal ISR, TLF was significantly decreased in DES compared with DCB group (Before PSM, HR: 0.43; 95% CI: 0.29-0.63; p <0.001; After PSM, HR: 0.33; 95% CI: 0.19-0.59; p < 0.001), which was mainly attributed to the lower incidence of clinically indicated target lesion revascularization (CD-TLR) (Before PSM, HR: 0.39; 95% CI: 0.26-0.59; p < 0.001; After PSM, HR: 0.28; 95% CI: 0.15-0.54; p < 0.001). Conclusions: The clinical outcomes for DES and DCB treatment are similar in focal type of ISR lesions. For non- focal ISR, the treatment of DES showed a significant decrease in TLF which was mainly attributed to a lower incidence of CD-TLR.
引用
收藏
页数:8
相关论文
共 39 条
  • [1] 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents
    Alfonso, Fernando
    Jose Perez-Vizcayno, Maria
    Cuesta, Javier
    Garcia del Blanco, Bruno
    Garcia-Touchard, Arturo
    Ramon Lopez-Minguez, Jose
    Masotti, Monica
    Zueco, Javier
    Cequier, Angel
    Velazquez, Maite
    Moreno, Raul
    Mainar, Vicente
    Dominguez, Antonio
    Moris, Cesar
    Molina, Eduardo
    Rivero, Fernando
    Jimenez-Quevedo, Pilar
    Gonzalo, Nieves
    Fernandez-Perez, Cristina
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (10) : 981 - 991
  • [2] A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents The RIBS IV Randomized Clinical Trial
    Alfonso, Fernando
    Perez-Vizcayno, Maria Jose
    Cardenas, Alberto
    del Blanco, Bruno Garcia
    Garcia-Touchard, Arturo
    Lopez-Minguez, Jose Ramon
    Benedicto, Amparo
    Masotti, Monica
    Zueco, Javier
    Iniguez, Andres
    Velazquez, Maite
    Moreno, Raul
    Mainar, Vicente
    Dominguez, Antonio
    Pomar, Francisco
    Melgares, Rafael
    Rivero, Fernando
    Jimenez-Quevedo, Pilar
    Gonzalo, Nieves
    Fernandez, Cristina
    Macaya, Carlos
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (01) : 23 - 33
  • [3] Current Treatment of In-Stent Restenosis
    Alfonso, Fernando
    Byrne, Robert A.
    Rivero, Fernando
    Kastrati, Adnan
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (24) : 2659 - 2673
  • [4] A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal Stent-In-Stent Restenosis
    Alfonso, Fernando
    Jose Perez-Vizcayno, Maria
    Cardenas, Alberto
    Garcia del Blanco, Bruno
    Seidelberger, Bernhard
    Iniguez, Andres
    Gomez-Recio, Manuel
    Masotti, Monica
    Teresa Velazquez, M.
    Sanchis, Juan
    Garcia-Touchard, Arturo
    Zueco, Javier
    Bethencourt, Armando
    Melgares, Rafael
    Cequier, Angel
    Dominguez, Antonio
    Mainar, Vicente
    Lopez-Minguez, Jose R.
    Moreu, Jose
    Marti, Vicens
    Moreno, Raul
    Jimenez-Quevedo, Pilar
    Gonzalo, Nieves
    Fernandez, Cristina
    Macaya, Carlos
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (14) : 1378 - 1386
  • [5] Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon
    Ali, Rosli Mohd
    Kader, Muhamad Ali S. K. Abdul
    Ahmad, Wan Azman Wan
    Ong, Tiong Kiam
    Liew, Houng Bang
    Omar, Al-Fazir
    Zuhdi, Ahmad Syadi Mahmood
    Nuruddin, Amin Ariff
    Schnorr, Beatrix
    Scheller, Bruno
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (06) : 558 - 566
  • [6] Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial
    Byrne, Robert A.
    Neumann, Franz-Josef
    Mehilli, Julinda
    Pinieck, Susanne
    Wolff, Britta
    Tiroch, Klaus
    Schulz, Stefanie
    Fusaro, Massimiliano
    Ott, Ilka
    Ibrahim, Tareq
    Hausleiter, Joerg
    Valina, Christian
    Pache, Juergen
    Laugwitz, Karl-Ludwig
    Massberg, Steffen
    Kastrati, Adnan
    [J]. LANCET, 2013, 381 (9865) : 461 - 467
  • [7] Drug-eluting stent restenosis - The pattern predicts the outcome
    Cosgrave, John
    Melzi, Gloria
    Biondi-Zoccai, Giuseppe G. L.
    Airoldi, Flavio
    Chieffo, Alaide
    Sangiorgi, Giuseppe M.
    Montorfano, Matteo
    Michev, Iassen
    Carlino, Mauro
    Bonizzoni, Erminio
    Colombo, Antonio
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (12) : 2399 - 2404
  • [8] Clinical end points in coronary stent trials - A case for standardized definitions
    Cutlip, Donald E.
    Windecker, Stephan
    Mehran, Roxana
    Boam, Ashley
    Cohen, David J.
    van Es, Gerrit-Anne
    Steg, P. Gabriel
    Morel, Marie-angele
    Mauri, Laura
    Vranckx, Pascal
    McFadden, Eugene
    Lansky, Alexandra
    Hamon, Martial
    Krucoff, Mitchell W.
    Serruys, Patrick W.
    [J]. CIRCULATION, 2007, 115 (17) : 2344 - 2351
  • [9] Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical (DAEDALUS study)
    Giacoppo, Daniele
    Alfonso, Fernando
    Xu, Bo
    Claessen, Bimmer E. P. M.
    Adriaenssens, Tom
    Jensen, Christoph
    Perez-Vizcayno, Maria J.
    Kang, Yoon
    Degenhardt, Ralf
    Pleva, Leos
    Baan, Jan
    Cuesta, Javier
    Park, Duk-Woo
    Schunkert, Heribert
    Colleran, Roisin
    Kukla, Pavel
    Jimenez-Quevedo, Pilar
    Unverdorben, Martin
    Gao, Runlin
    Naber, Christoph K.
    Park, Seung-Jung
    Henriques, Jose P. S.
    Kastrati, Adnan
    Byrne, Robert A.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (38) : 3715 - 3728
  • [10] Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients
    Giacoppo, Daniele
    Gargiulo, Giuseppe
    Aruta, Patrizia
    Capranzano, Piera
    Tamburino, Corrado
    Capodanno, Davide
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 351